Organization
Centre Henri Becquerel
1 clinical trial
7 abstracts
Abstract
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.Org: Gustave Roussy Cancer Center, CARIO - HPCA, Department of Genetics, Claudius Regaud Institute, Eugène Marquis Comprehensive Cancer Center,
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Clinical trial
Influence of Body Composition, Total Body Fat and Body Mass Index on the Pharmacokinetics of Docetaxel in Localized Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-05-02
Abstract
Prospective evaluation of factors associated with acceptance of feeding tube (FT) placement and clinical outcomes during radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinoma (HNSCC).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Centre Henri Becquerel, Centre H. Becquerel, Cancer Centre Henri Becquerel, Rouen, France,
Abstract
Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).Org: INSERM Unit 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy, Villejuif, France, Institut Curie, Saint Cloud, France,
Abstract
Predicting non-small cell lung cancer response to immune checkpoint inhibitors with machine learning based on heterogeneous biomarkers.Org: INRIA, Sophia Antipolis, Centre Antoine Lacassagne, Center hospitalier Princesse-Grace, Univ Rouen Normandie,
Abstract
Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Curie, Saint Cloud, France, APHP-INSERM U1149 Universite Paris Diderot, Curie Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,